Loading
A phase 1/2 trial of DM005 in non-small-cell lung cancer and head and neck squamous cell carcinoma, run by Doma Biopharmaceutical（Suzhou）Co., Ltd., now recruiting.
A Study of DM005 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06515990 by Doma Biopharmaceutical（Suzhou）Co., Ltd., with 208 participants planned, started 2024-10-31 and due to reach its primary completion in 2027-03. Interventions recorded: DM005.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/